<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=5903&amp;modal=1&amp;valnames=exclusion_criteria&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="502550" class="table-">
                
                <td>June 25, 2024, noon</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria">
            * medical or family history of convulsions, epilepsy, encephalopathy, and psychosis disorders;
* history of allergies to any ingredient of ad5-ncov, history of serious allergic reactions to any vaccine, history of allergies and immune diseases;
* women who are pregnant or lactating, positive urine pregnancy test or plan to become pregnant during the 12 months study period;
* acute febrile diseases and infectious diseases, medical history of sars (sars-cov-1);
* serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and uncontrollable medications (on-site measurement for 18-59 years of age: systolic blood pressure ≥160mmhg, diastolic blood pressure ≥100mmhg), etc;
* severe chronic diseases or with advanced stage conditions which cannot be controlled smoothly, such as diabetes, thyroid disease, etc;
* congenital or acquired angioedema/neurological edema;
* urticaria history within 1 year before receiving the study vaccine;
* asplenia or functional aspleenia;
* thrombocytopenia or other coagulation disorders (may cause contraindications for intramuscular injection);
* trypanophobia；
* history of receiving immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, nebulized corticosteroid therapy in the past 6 months (not including corticosteroid spray treatment for allergic rhinitis, and surface corticosteroid treatment for acute non-complicated dermatitis);
* prior administration of blood products in last 4 months;
* received other investigational drugs within 1 month before the study;
* prior administration of live attenuated vaccines within 1 month before the study;
* prior administration of subunit or inactivated vaccines within 14 days before the study;
* current anti-tuberculosis therapy;
* medical history of covid-19 disease/infection;
* any condition that in the opinion of the investigators may interfere with the participants&#x27; compliance or evaluation of study objectives or informed consent (i.e. medical, psychological, social or other conditions, etc.).
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria validated">
            * medical or family history of convulsions, epilepsy, encephalopathy, and psychosis disorders;
* history of allergies to any ingredient of ad5-ncov, history of serious allergic reactions to any vaccine, history of allergies and immune diseases;
* women who are pregnant or lactating, positive urine pregnancy test or plan to become pregnant during the 12 months study period;
* acute febrile diseases and infectious diseases, medical history of sars (sars-cov-1);
* serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and uncontrollable medications (on-site measurement for 18-59 years of age: systolic blood pressure ≥160mmhg, diastolic blood pressure ≥100mmhg), etc;
* severe chronic diseases or with advanced stage conditions which cannot be controlled smoothly, such as diabetes, thyroid disease, etc;
* congenital or acquired angioedema/neurological edema;
* urticaria history within 1 year before receiving the study vaccine;
* asplenia or functional aspleenia;
* thrombocytopenia or other coagulation disorders (may cause contraindications for intramuscular injection);
* trypanophobia；
* history of receiving immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, nebulized corticosteroid therapy in the past 6 months (not including corticosteroid spray treatment for allergic rhinitis, and surface corticosteroid treatment for acute non-complicated dermatitis);
* prior administration of blood products in last 4 months;
* received other investigational drugs within 1 month before the study;
* prior administration of live attenuated vaccines within 1 month before the study;
* prior administration of subunit or inactivated vaccines within 14 days before the study;
* current anti-tuberculosis therapy;
* medical history of covid-19 disease/infection;
* any condition that in the opinion of the investigators may interfere with the participants&#x27; compliance or evaluation of study objectives or informed consent (i.e. medical, psychological, social or other conditions, etc.).
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="123206" class="table-">
                
                <td>June 10, 2021, 12:33 a.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria">
            -  medical or family history of convulsions, epilepsy, encephalopathy, and psychosis
             disorders;

          -  history of allergies to any ingredient of ad5-ncov, history of serious allergic
             reactions to any vaccine, history of allergies and immune diseases;

          -  women who are pregnant or lactating, positive urine pregnancy test or plan to become
             pregnant during the 12 months study period;

          -  acute febrile diseases and infectious diseases, medical history of sars (sars-cov-1);

          -  serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial
             infarction, severe hypertension and uncontrollable medications (on-site measurement
             for 18-59 years of age: systolic blood pressure ≥160mmhg, diastolic blood pressure
             ≥100mmhg), etc;

          -  severe chronic diseases or with advanced stage conditions which cannot be controlled
             smoothly, such as diabetes, thyroid disease, etc;

          -  congenital or acquired angioedema/neurological edema;

          -  urticaria history within 1 year before receiving the study vaccine;

          -  asplenia or functional aspleenia;

          -  thrombocytopenia or other coagulation disorders (may cause contraindications for
             intramuscular injection);

          -  trypanophobia；

          -  history of receiving immunosuppressant therapy, anti-allergic therapy, cytotoxic
             therapy, nebulized corticosteroid therapy in the past 6 months (not including
             corticosteroid spray treatment for allergic rhinitis, and surface corticosteroid
             treatment for acute non-complicated dermatitis);

          -  prior administration of blood products in last 4 months;

          -  received other investigational drugs within 1 month before the study;

          -  prior administration of live attenuated vaccines within 1 month before the study;

          -  prior administration of subunit or inactivated vaccines within 14 days before the
             study;

          -  current anti-tuberculosis therapy;

          -  medical history of covid-19 disease/infection;

          -  any condition that in the opinion of the investigators may interfere with the
             participants&#x27; compliance or evaluation of study objectives or informed consent (i.e.
             medical, psychological, social or other conditions, etc.).
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="exclusion_criteria validated">
            -  medical or family history of convulsions, epilepsy, encephalopathy, and psychosis
             disorders;

          -  history of allergies to any ingredient of ad5-ncov, history of serious allergic
             reactions to any vaccine, history of allergies and immune diseases;

          -  women who are pregnant or lactating, positive urine pregnancy test or plan to become
             pregnant during the 12 months study period;

          -  acute febrile diseases and infectious diseases, medical history of sars (sars-cov-1);

          -  serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial
             infarction, severe hypertension and uncontrollable medications (on-site measurement
             for 18-59 years of age: systolic blood pressure ≥160mmhg, diastolic blood pressure
             ≥100mmhg), etc;

          -  severe chronic diseases or with advanced stage conditions which cannot be controlled
             smoothly, such as diabetes, thyroid disease, etc;

          -  congenital or acquired angioedema/neurological edema;

          -  urticaria history within 1 year before receiving the study vaccine;

          -  asplenia or functional aspleenia;

          -  thrombocytopenia or other coagulation disorders (may cause contraindications for
             intramuscular injection);

          -  trypanophobia；

          -  history of receiving immunosuppressant therapy, anti-allergic therapy, cytotoxic
             therapy, nebulized corticosteroid therapy in the past 6 months (not including
             corticosteroid spray treatment for allergic rhinitis, and surface corticosteroid
             treatment for acute non-complicated dermatitis);

          -  prior administration of blood products in last 4 months;

          -  received other investigational drugs within 1 month before the study;

          -  prior administration of live attenuated vaccines within 1 month before the study;

          -  prior administration of subunit or inactivated vaccines within 14 days before the
             study;

          -  current anti-tuberculosis therapy;

          -  medical history of covid-19 disease/infection;

          -  any condition that in the opinion of the investigators may interfere with the
             participants&#x27; compliance or evaluation of study objectives or informed consent (i.e.
             medical, psychological, social or other conditions, etc.).
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
June 25, 2024, noon	usa	* medical or family history of convulsions, epilepsy, encephalopathy, and psychosis disorders; * history of allergies to any ingredient of ad5-ncov, history of serious allergic reactions to any vaccine, history of allergies and immune diseases; * women who are pregnant or lactating, positive urine pregnancy test or plan to become pregnant during the 12 months study period; * acute febrile diseases and infectious diseases, medical history of sars (sars-cov-1); * serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and uncontrollable medications (on-site measurement for 18-59 years of age: systolic blood pressure ≥160mmhg, diastolic blood pressure ≥100mmhg), etc; * severe chronic diseases or with advanced stage conditions which cannot be controlled smoothly, such as diabetes, thyroid disease, etc; * congenital or acquired angioedema/neurological edema; * urticaria history within 1 year before receiving the study vaccine; * asplenia or functional aspleenia; * thrombocytopenia or other coagulation disorders (may cause contraindications for intramuscular injection); * trypanophobia； * history of receiving immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, nebulized corticosteroid therapy in the past 6 months (not including corticosteroid spray treatment for allergic rhinitis, and surface corticosteroid treatment for acute non-complicated dermatitis); * prior administration of blood products in last 4 months; * received other investigational drugs within 1 month before the study; * prior administration of live attenuated vaccines within 1 month before the study; * prior administration of subunit or inactivated vaccines within 14 days before the study; * current anti-tuberculosis therapy; * medical history of covid-19 disease/infection; * any condition that in the opinion of the investigators may interfere with the participants' compliance or evaluation of study objectives or informed consent (i.e. medical, psychological, social or other conditions, etc.).	* medical or family history of convulsions, epilepsy, encephalopathy, and psychosis disorders; * history of allergies to any ingredient of ad5-ncov, history of serious allergic reactions to any vaccine, history of allergies and immune diseases; * women who are pregnant or lactating, positive urine pregnancy test or plan to become pregnant during the 12 months study period; * acute febrile diseases and infectious diseases, medical history of sars (sars-cov-1); * serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and uncontrollable medications (on-site measurement for 18-59 years of age: systolic blood pressure ≥160mmhg, diastolic blood pressure ≥100mmhg), etc; * severe chronic diseases or with advanced stage conditions which cannot be controlled smoothly, such as diabetes, thyroid disease, etc; * congenital or acquired angioedema/neurological edema; * urticaria history within 1 year before receiving the study vaccine; * asplenia or functional aspleenia; * thrombocytopenia or other coagulation disorders (may cause contraindications for intramuscular injection); * trypanophobia； * history of receiving immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, nebulized corticosteroid therapy in the past 6 months (not including corticosteroid spray treatment for allergic rhinitis, and surface corticosteroid treatment for acute non-complicated dermatitis); * prior administration of blood products in last 4 months; * received other investigational drugs within 1 month before the study; * prior administration of live attenuated vaccines within 1 month before the study; * prior administration of subunit or inactivated vaccines within 14 days before the study; * current anti-tuberculosis therapy; * medical history of covid-19 disease/infection; * any condition that in the opinion of the investigators may interfere with the participants' compliance or evaluation of study objectives or informed consent (i.e. medical, psychological, social or other conditions, etc.).
June 10, 2021, 12:33 a.m.	usa	- medical or family history of convulsions, epilepsy, encephalopathy, and psychosis disorders; - history of allergies to any ingredient of ad5-ncov, history of serious allergic reactions to any vaccine, history of allergies and immune diseases; - women who are pregnant or lactating, positive urine pregnancy test or plan to become pregnant during the 12 months study period; - acute febrile diseases and infectious diseases, medical history of sars (sars-cov-1); - serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and uncontrollable medications (on-site measurement for 18-59 years of age: systolic blood pressure ≥160mmhg, diastolic blood pressure ≥100mmhg), etc; - severe chronic diseases or with advanced stage conditions which cannot be controlled smoothly, such as diabetes, thyroid disease, etc; - congenital or acquired angioedema/neurological edema; - urticaria history within 1 year before receiving the study vaccine; - asplenia or functional aspleenia; - thrombocytopenia or other coagulation disorders (may cause contraindications for intramuscular injection); - trypanophobia； - history of receiving immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, nebulized corticosteroid therapy in the past 6 months (not including corticosteroid spray treatment for allergic rhinitis, and surface corticosteroid treatment for acute non-complicated dermatitis); - prior administration of blood products in last 4 months; - received other investigational drugs within 1 month before the study; - prior administration of live attenuated vaccines within 1 month before the study; - prior administration of subunit or inactivated vaccines within 14 days before the study; - current anti-tuberculosis therapy; - medical history of covid-19 disease/infection; - any condition that in the opinion of the investigators may interfere with the participants' compliance or evaluation of study objectives or informed consent (i.e. medical, psychological, social or other conditions, etc.).	- medical or family history of convulsions, epilepsy, encephalopathy, and psychosis disorders; - history of allergies to any ingredient of ad5-ncov, history of serious allergic reactions to any vaccine, history of allergies and immune diseases; - women who are pregnant or lactating, positive urine pregnancy test or plan to become pregnant during the 12 months study period; - acute febrile diseases and infectious diseases, medical history of sars (sars-cov-1); - serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension and uncontrollable medications (on-site measurement for 18-59 years of age: systolic blood pressure ≥160mmhg, diastolic blood pressure ≥100mmhg), etc; - severe chronic diseases or with advanced stage conditions which cannot be controlled smoothly, such as diabetes, thyroid disease, etc; - congenital or acquired angioedema/neurological edema; - urticaria history within 1 year before receiving the study vaccine; - asplenia or functional aspleenia; - thrombocytopenia or other coagulation disorders (may cause contraindications for intramuscular injection); - trypanophobia； - history of receiving immunosuppressant therapy, anti-allergic therapy, cytotoxic therapy, nebulized corticosteroid therapy in the past 6 months (not including corticosteroid spray treatment for allergic rhinitis, and surface corticosteroid treatment for acute non-complicated dermatitis); - prior administration of blood products in last 4 months; - received other investigational drugs within 1 month before the study; - prior administration of live attenuated vaccines within 1 month before the study; - prior administration of subunit or inactivated vaccines within 14 days before the study; - current anti-tuberculosis therapy; - medical history of covid-19 disease/infection; - any condition that in the opinion of the investigators may interfere with the participants' compliance or evaluation of study objectives or informed consent (i.e. medical, psychological, social or other conditions, etc.).